
KN026/Chemo Meets PFS End Point in HER2+ Gastric Cancer in 2L Setting
KN026, an anti-HER2 bispecific antibody, administered with chemotherapy met the pre-specified primary end point of progression-free survival (PFS) with statistical significance and clinical relevance in the second-line or above treatment of patients with …